{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-228133","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-05-18T13:33:34+00:00","discovered_at":"2026-05-18T13:35:00.399557+00:00","generated_at":"2026-05-18T13:37:27.384581+00:00","sec_items":["1.01","5.03","2.01","3.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts","bullets":["Acquisition closed May 18; Quince issued 3.26M shares and 67K Series C Preferred to Orphai holders.","Pre-transaction Quince holders will own ~6.9% post-financing; new Investors hold ~61.2%.","PIPE of $115M via sale of Series C Preferred and warrants; warrants could add ~$72M.","Dr. Brigette Roberts appointed to Board and as Chief of Corporate Affairs; salary $600K.","Retention bonuses of $700K for CEO Dirk Thye and $500K for COO Brendan Hannah, contingent on stockholder approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-228133","json":"https://secwatch.observer/filing/0001193125-26-228133.json","markdown":"https://secwatch.observer/filing/0001193125-26-228133.md","text":"https://secwatch.observer/filing/0001193125-26-228133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/0001193125-26-228133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/d109149d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T13:37:27.384581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a002a3f342","claim":"Brigette Roberts was appointed as Director at Quince Therapeutics, Inc..","evidence_excerpt":"Brigette Roberts, M.D., was appointed to the Board as a Class III director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/0001193125-26-228133-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c7ca156625","claim":"Brigette Roberts was appointed as Chief of Corporate Affairs at Quince Therapeutics, Inc..","evidence_excerpt":"Dr. Roberts was also appointed as the Chief of Corporate Affairs of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/0001193125-26-228133-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief of Corporate Affairs"}],"fact_type":"executive_change"},{"claim_id":"324a95a10c5cc6c346bc1fb3a4e2c5ec6200ea3d","claim":"Quince Therapeutics, Inc.: Filed Certificate of Designation creating Series C Preferred Stock (effective 2026-05-18).","evidence_excerpt":"On May 18, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the \" Certificate of Designation \") in connection with the Acquisition and the Financing referenced in Item 1.01 above.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/0001193125-26-228133-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-05-18"}],"fact_type":"governance_change"},{"claim_id":"698b5812eafab21549d9829736315ebce342e4c2","claim":"Quince Therapeutics, Inc. completed an acquisition involving Orphai Therapeutics, LLC and Orphai Holdings Therapeutics, Inc. (closed 2026-05-18).","evidence_excerpt":"On May 18, 2026, the Company completed its acquisition of the Orphai Entities.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/0001193125-26-228133-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Orphai Therapeutics, LLC and Orphai Holdings Therapeutics, Inc."},{"label":"Closing","value":"2026-05-18"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}